Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool January 5, 2007 Matthew Crews	Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool June 11, 2007 Mike Cianciolo	Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.
The Motley Fool September 25, 2009 Chris Jones	The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system.
The Motley Fool June 27, 2011 Shubh Datta	All Is Not Yet Right at Rite Aid Drug retailer Rite Aid posts losses in its first fiscal quarter and sees further losses ahead.
The Motley Fool January 4, 2005 Seth Jayson	Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.
The Motley Fool September 29, 2011 Navjot Kaur	Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool June 25, 2004 Steven Mallas	Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?
The Motley Fool September 22, 2010 Rich Smith	Foolish Forecast: A Prescription for Rite Aid Investors Here's what you need to know before earnings come out tomorrow.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool August 19, 2011 Ilan Moscovitz	Rite Aid Is Cheaper Than You Think Rite Aid tends to generate much more free cash flow than net income, suggesting that -- while things may not exactly be going swimmingly -- the company's stock might be a bit cheaper than many investors realize.
The Motley Fool April 8, 2004 Seth Jayson	Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.
The Motley Fool March 8, 2005 Seth Jayson	Rite Aid Wretched? Value investors may be interested in Rite Aid.
The Motley Fool September 7, 2004 Seth Jayson	Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth.
The Motley Fool September 24, 2004 Seth Jayson	Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool June 24, 2005 Stephen D. Simpson	Is Rite Aid a Real Value Stock? Reality hasn't caught up with the company's turnaround prospects. Rite Aid must deal with a lot of debt and preferred equity if and when it recovers.
The Motley Fool September 29, 2011 Dan Caplinger	Has Rite Aid Become the Perfect Stock? The company needs to turn itself around first before anyone will seriously expect superior results from Rite Aid.
The Motley Fool April 11, 2008 Ryan Fuhrmann	Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd.
The Motley Fool June 25, 2007 Ryan Fuhrmann	Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool September 26, 2007 Ryan Fuhrmann	Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see.
The Motley Fool October 4, 2005 Seth Jayson	Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
The Motley Fool September 22, 2005 Stephen D. Simpson	Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.
The Motley Fool April 5, 2006 Rich Smith	Foolish Forecast: Rite Aid Writes a Script Although the retail pharmacy isn't setting the world on fire with its turnaround, its gross margins have inched up slightly over the last 18 months. Investors, take note.
The Motley Fool November 23, 2008 Todd Wenning	A Value Stock to Avoid in This Market Rite Aid is one "value" to avoid in this market.
The Motley Fool February 4, 2005 Steven Mallas	Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool May 2, 2006 Alyce Lomax	Insane CEO Pay As investors, it can often be sobering to take a hard look at management compensation information in a company's proxy materials. Should shareholders say enough's enough?
The Motley Fool January 3, 2012 Shubh Datta	Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.
The Motley Fool June 21, 2006 Rich Smith	Foolish Forecast: Rite Aid Revival? Will tomorrow's earnings news make it three bad quarters in a row for the retail pharmacy? Investors, take note.
The Motley Fool December 16, 2004 Nathan Slaughter	Rx: Get Some Earnings Quick The No. 3 drug chain Rite Aid posts a sharp drop in earnings and slashes guidance again.
The Motley Fool July 6, 2004 Steven Mallas	Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool May 28, 2010 Alyce Lomax	Jerks and Their Perks When these folks push, shareholders need to push back.
The Motley Fool April 4, 2007 Timothy M. Otte	Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.
The Motley Fool April 15, 2009 Alyce Lomax	CEOs: Do the Right Thing! 2008 was a bad year for shareholders and workers. Some CEOs made out like bandits, though.
The Motley Fool June 29, 2005 Rich Smith	Stupid CEO Tricks When it comes to executive compensation, you don't always get what you pay for. If your company is too busy making its CEO rich to make you rich, then it might be time to find a better investment.
The Motley Fool April 12, 2007 Ryan Fuhrmann	Rite Aid Ekes Out a Gain: Fool by Numbers The drugstore retailer released fourth-quarter and year-end 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool November 9, 2005 Steven Mallas	CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool March 26, 2007 Ryan Fuhrmann	A Healthy Shade of Walgreen: Fool by Numbers The drugstore chain released second-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool April 21, 2008 Tom Hutchinson	Big Labor Blames Glutton CEOs The AFL-CIO cast itself this week as a modern-day Robin Hood, urging support for legislation that both curtails excessive executive pay and provides aid to home foreclosure "victims."